07-May-2021 - Universität Zürich

Defective Epithelial Barriers Linked to Two Billion Chronic Diseases

Rise in allergic and autoimmune conditions

Humans are exposed to a variety of toxins and chemicals every day. According to the epithelial barrier hypothesis, exposure to many of these substances damages the epithelium, the thin layer of cells that covers the surface of our skin, lungs and intestine. Defective epithelial barriers have been linked to a rise in almost two billion allergic, autoimmune, neurodegenerative and psychiatric diseases.

Epithelial cells form the covering of most internal and external surfaces of the human body. This protective layer acts as a defense against invaders – including bacteria, viruses, environmental toxins, pollutants and allergens. If the skin and mucosal barriers are damaged or leaky, foreign agents such as bacteria can enter into the tissue and cause local, often chronic inflammation. This has both direct and indirect consequences.

Chronic diseases due to defective epithelial barriers

Cezmi Akdis, Director of the Swiss Institute of Allergy and Asthma Research (SIAF), which is associated with the University of Zurich (UZH), has now published a comprehensive summary of the research on epithelial barrier damage in Nature Reviews Immunology. “The epithelial barrier hypothesis proposes that damages to the epithelial barrier are responsible for up to two billion chronic, non-infectious diseases,” Professor Akdis says. In the past 20 years, researchers at the SIAF alone published more than 60 articles on how various substances damage the epithelial cells of a number of organs.

Rise in allergic and autoimmune conditions

The epithelial barrier hypothesis provides an explanation as to why allergies and autoimmune diseases have been increasing for decades – they are linked to industrialization, urbanization and westernized lifestyle. Today many people are exposed to a wide range of toxins, such as ozone, nanoparticles, microplastics, household cleaning agents, pesticides, enzymes, emulsifiers, fine dust, exhaust fumes, cigarette smoke and countless chemicals in the air, food and water. “Next to global warming and viral pandemics such as COVID-19, these harmful substances represent one of the greatest threats to humankind,” emphasizes Akdis.

Asthma, Alzheimer’s et al.

Local epithelial damage to the skin and mucosal barriers lead to allergic conditions, inflammatory bowel disorders and celiac disease. But disruptions to the epithelial barrier can also be linked to many other diseases that are characterized by changes in the microbiome. Either the immune system erroneously attacks “good” bacteria in healthy bodies or it targets pathogenic – i.e. “bad” – invaders.  In the gut, leaky epithelial barriers and microbial imbalance contribute to the onset or development of chronic autoimmune and metabolic diseases such as diabetes, obesity, rheumatoid arthritis, multiple sclerosis or ankylosing spondylitis. Moreover, defective epithelial barriers have also been linked to neurodegenerative and psychiatric diseases such as Parkinson’s disease, Alzheimer’s disease, autism spectrum disorders and chronic depression, which may be triggered or aggravated by distant inflammatory responses and changes in the gut’s microbiome.

Prevention, intervention – and more research

“There is a great need to continue research into the epithelial barrier to advance our understanding of molecular mechanisms and develop new approaches for prevention, early intervention and therapy,” says Akdis. Novel therapeutic approaches could focus on strengthening tissue-specific barriers, blocking bacteria or avoiding colonization by pathogens. Other strategies to reduce diseases may involve the microbiome, for example through targeted dietary measures. Last but not least, the focus must also be on avoiding and reducing exposure to harmful substances and developing fewer toxic products.

Facts, background information, dossiers
More about Universität Zürich
  • News

    Cholesterol Levels Sustainably Lowered Using Base Editing

    Base editing is a novel gene editing approach that can precisely change individual building blocks in a DNA sequence. By installing such a point mutation in a specific gene, an international research team led by the University of Zurich has succeeded in sustainably lowering high LDL cholest ... more

    New Technology Makes Tumor Eliminate Itself

    A new technology developed by UZH researchers enables the body to produce therapeutic agents on demand at the exact location where they are needed. The innovation could re-duce the side effects of cancer therapy and may hold the solution to better delivery of Covid-related therapies directl ... more

    Biomarker Detects Severe COVID-19 Early On

    Severe cases of COVID-19 can now be detected at an early stage. Researchers at the University of Zurich have identified the first biomarker that can reliably predict which patients will develop severe symptoms. This can help to improve the treatment of severe cases of COVID-19. Most people ... more